Jim Cramer Says J&J's Quarter Wasn't That Bad, but He Can't Jump on Pharma Stocks Right Now
Jim Cramer thought Johnson & Johnson's results were decent but he remains cautious on pharma.
TheStreet's Jim Cramer says Johnson & Johnson's (JNJ) - Get Report results weren't bad, but he's still cautious on pharma stocks given the political environment.
